Direct-to-Consumer Drug Advertisements and Their Effects on Doctor-Patient Relationships by DeLeon-Dowd, Alicia
Regis University 
ePublications at Regis University 
All Regis University Theses 
Spring 2017 
Direct-to-Consumer Drug Advertisements and Their Effects on 
Doctor-Patient Relationships 
Alicia DeLeon-Dowd 
Follow this and additional works at: https://epublications.regis.edu/theses 
Recommended Citation 
DeLeon-Dowd, Alicia, "Direct-to-Consumer Drug Advertisements and Their Effects on Doctor-Patient 
Relationships" (2017). All Regis University Theses. 807. 
https://epublications.regis.edu/theses/807 
This Thesis - Open Access is brought to you for free and open access by ePublications at Regis University. It has 
been accepted for inclusion in All Regis University Theses by an authorized administrator of ePublications at Regis 
University. For more information, please contact epublications@regis.edu. 
   
 
 
 
 i 
 
 
 
 
DIRECT-TO-CONSUMER DRUG ADVERTISEMENTS AND THEIR 
EFFECTS ON DOCTOR-PATIENT RELATIONSHIPS 
 
 
A thesis submitted to 
Regis College 
The Honors Program  
in partial fulfillment of the requirements  
for Graduation with Honors    
 
by 
Alicia DeLeon-Dowd 
 
 
 
 
May 2017  
 
 
 ii 
 
Thesis written by 
Alicia DeLeon-Dowd  
 
 
 
 
 
 
Approved by 
 
  
Thesis Advisor 
 
 
Thesis Reader 
 
Accepted by 
 
 
Director, University Honors Program 
 iii 
 
  
 iv 
TABLE OF CONTENTS 
List of Figures          v 
ACKNOWLEDGEMENTS        vi  
I. INTRODUCTION       1 
II. ROLE OF THE PHYSICIAN      12 
III. BRIEF HISTORY OF DRUG MARKETING    19  
IV. DRUG ADVERTISEMENTS TODAY     26 
V. PERSONALIZED MEDICINE      55 
FINAL THOUGHTS         64 
REFERENCES         66 
 
 
 
 
 
 
 
 
 
 
 
 v 
LIST OF FIGURES 
Figure 1. Image showing the role Christianity played in medicine during the  
middle ages (Medieval Life, 2013).       4 
Figure 2. William Harvey discovered the circulation of during the  
Scientific Revolution (Schultz, 2002).      5 
Figure 3. Example of a drug advertisement prior to the enactment of the  
Federal Food, Drug, and Cosmetic Act in 1906 (Say Yes to Drugs?, 2014). 20 
Figure 4. Screen grabs from the first broadcasted drug advertisement by Boots 
pharmaceuticals promoting their product, Rufen, a pain relieve (Scott, 2015). 22 
Figure 5. Top figure shows the amount of spending in billions  on drug  
advertisements from 1998 to 2009. Bottom shows FDA enforcement of  
regulations regarding DTC advertisments. As spending on drug  
advertisements increase, FDA enforcement decreases (Ventola, 2011).   28 
Figure 6. A model showing the effects of DTC advertisements  
(Frosch et al., 2010).          29 
Figure 7. Advertisement for Humira (Bulik, 2016).     35 
Figure 8. Data from the first quarter of 2008 to the third quarter in 2015  
showing an increase in the cost of EpiPen (Koons & Langreth, 2015).   39 
 
 
 
 vi 
ACKNOWLEDGEMENTS 
 I would first like to acknowledge my thesis advisor, Dr. Franco. It has been 
through her dedication and commitment to this project that has allowed for its successful 
completion. She has worked diligently with me, making sure everything is the best it can 
be. In addition, I would also like to thank my reader, Dr. DiSanto. He has provided me 
with insightful feedback, and he has made sure that all of my arguments are coherent. I 
would also like to thank my family and friends. Without their support and constant 
encouragement, I would have not been able to complete this project. They always believe 
that I can achieve anything my mind to, and this thesis is evident of that. Lastly, I would 
like to thank the Regis University Honors Program, Dr. Howe and Dr. Kleier. The 
Honors program challenges it students to think on a deeper level and to always be 
passionate in everything that they do. I am honored to have been a part of this program 
and believe that it has laid a foundation for my success in the future.   
 
 
 
 
 
 
 
 
 1 
I. Introduction 
Medicine has had a very significant impact on my life. When I just 5 years old, 
my mom was diagnosed with breast cancer. Having beaten the disease, we felt that we, as 
a family, were in the clear. Fast-forward to the beginning of high school, and my world 
was changed. My dad had three surgeries, one hip replacement and two to replace 
femoral hairline fractures, in three months. Our lives never really went back to “normal”, 
and I have not seen my dad walk without some sort of assistance since. So my 
relationship with medicine and with doctors has been somewhat complicated. I have seen 
the wonders they can do, which I will discuss more later in this chapter. I have also seen 
how it can fail and change lives not necessarily for the better. There are many factors that 
determine the outcomes of certain diseases, but I believe that one of the most important is 
the doctor-patient relationship. There are also many factors that can affect that 
relationship, one of them being direct-to-consumer (DTC) drug advertisements. However, 
before explicitly discussing how DTC advertisements affect doctor-patient relationships, 
it is important to give some context as to how the medical field has evolved to what we 
know it to be today. In doing so, we will have the necessary foundation to understand 
how and why DTC advertisements affect doctor-patient relationships. 
 To begin, medicine, or rather the study and practice of medicine, has existed in 
every period of history where people have had to deal with disease and illness and had to 
find a way of resolving those ailments. How each period coped with its circumstances is a 
reflection of the time and the culture. Although some historians include ancient Egypt in 
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their discussions on the history of medicine, I will omit that period and begin with ancient 
Greece as it is more associated with the Western medical tradition. The most prominent 
figure to come out of ancient Greece was Hippocrates, who is widely known as the 
“Father of Medicine.” He wrote a collection of texts and essays that have led to the 
tradition of Hippocratic medicine, which is largely the foundation of Western medicine. 
This tradition greatly emphasizes the patient rather than the disease itself, and it 
established the well known motto “At least do no harm” (Magner, 1992). This motto is 
still recited by today’s physicians showing the lasting influence Hippocrates had. Along 
with explaining the role of the physician, Hippocrates was one of the first people to not 
blame the gods for the occurrence of the diseases because he believed that these diseases 
were a part of a natural process. Recognizing that there was not a causal relationship 
between the gods and disease is what Hippocrates believed made one a true physician 
(Magner, 1992). That is not to say Hippocrates did not believe in the gods, but he 
understood that nature played a pivotal role in medicine (Magner, 1992). With the insight 
of Hippocrates, the practice of medicine transitioned to a more rational way of thinking 
about disease. However, as time progressed into the Middle Ages, the Hippocratic 
tradition fell somewhat out of favor. 
Medicine in the Middle Ages can be characterized by a complex interplay 
between medicine and religion, more specifically Christianity. Because Christianity was 
so prevalent through society, there was a shift in how people viewed the body and how it 
should be treated. The Greeks desired a healthy human body while Christians maintained 
a somewhat repugnant view of the body. That is, Christians could not view the body as 
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something to be desired, especially in a sexual context. However, they did believe that it 
deserved some care and respect because the body houses the soul, which is given by God. 
These beliefs led to a different way of healing illnesses. It involved prayers, exorcisms, 
etc. while Hippocratic medicine utilized empirical practices such as drugs, diet, and 
simple surgeries. Thus, there was clear difference between religious medicine and human 
medicine. Religious medicine relied on prayers, exorcisms, etc. while human medicine 
valued the use of drugs and simple surgical operations (Magner, 1992). Although 
practicing human medicine was not looked down upon, it had an unstable relationship 
with the Church, and that relationship had to be acknowledged. As time continued on, 
medieval scholars determined medical studies to be “an integral part of Christian 
wisdom” (Magner, 1992). That is, if all knowledge came from God, that included 
medical knowledge, and it began to be seen as a more serious subject to be studied. Thus, 
medical education was formally established in universities, but very few practitioners 
actually had university training. Despite this, in the Middle Ages, began the process of 
establishing medicine as a formal profession that included an education, standardized 
curriculum, licensing, and legal regulation. It was also during this time that the first 
“hospitals” were established. This term is used loosely because our current organization 
of hospitals is vastly different than the one used in the Middle Ages (Magner, 1992). 
Medieval hospitals were established for largely religious reasons and not scientific ones 
(Figure 1).  
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Figure 1. Image showing the role Christianity played in medicine during the middle ages 
(Medieval Life, 2013). 
 
Medicine during ancient Greece utilized the practices established by Hippocrates 
while medicine during the Middle Ages was largely influenced by Christian tradition, but 
for both time periods, the treatments involved were not based on scientific reason. The 
Scientific Revolution was the beginning of the integration of medicine and science. 
Perhaps the most well known figure to come out of the Scientific Revolution, with 
regards to medicine, is William Harvey. Harvey discovered the circulation of the blood 
and changed the way people thought about the heart and the movement of blood 
(Magner, 1992). The Scientific Revolution also saw the use of phlebotomy and blood 
transfusions; although, neither of those practices would be perfected until an 
understanding of the immune system emerged (Figure 2). Nevertheless, the Scientific 
Revolution saw an increase in experimentation and began the process of using science to 
develop medical techniques. Although some of the techniques used were crude and 
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Figure 2. William Harvey discovered 
the circulation of during the Scientific 
Revolution (Schultz, 2002).   
 
 
ineffective, it showed the interest physicians had in learning more about the body and 
finding ways to treat its illnesses using more effective means. These practices lay the 
foundation for more scientific research and developing improved techniques to treat 
different illnesses.    
 
 
We can now enter into the modern era of medicine with scientists Louis Pasteur 
and Robert Koch leading the way. It was not until our understanding of microorganisms 
that scientists were able to develop treatments we are more familiar with today, and both 
Pasteur and Koch were instrumental in that understanding. Pasteur integrated several 
fields of science and is credited for identifying the role that microbes play in the 
fermentation process. Through these experiments, Pasteur became interested in 
disproving the spontaneous generation theory (Berche, 2012). In trying to show that 
microbes do not spontaneously generate in sterile medium, Pasteur developed the sterile 
techniques that gave way to modern microbiology and surgery (Magner, 1992). Pasteur 
was also a pioneer in the development of vaccines. Before developing a vaccine, he 
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became interested in infectious diseases during an epidemic of silkworms in southern 
France between 1865 and 1870 (Berche, 2012). Shortly thereafter, in 1878, Pasteur 
discovered a vaccine against fowl cholera. Like Pasteur, Koch, too, became interested in 
scientific research and began his work with Bacillus anthracis, more commonly known 
as anthrax. He discovered that bacteria could be cultured outside of the organism it was 
discovered in (Magner, 1992). He also discovered the bacteria that cause tuberculosis. 
Pasteur confirmed the causative role of B. anthracis (Berche, 2012). While Pasteur would 
go on to searching for a rabies vaccine, Koch began to research wound infection, and 
soon tuberculosis. The discoveries made by Pasteur and Koch, in conjunction with the 
germ theory, highlighted the idea that diseases could be controlled, and perhaps even 
stopped. It had implications for public health and triggered government-paid investigators 
to determine the sources of infection. It created a government-regulated medical 
profession, and “hospitals became one of the chief sites for scientific medicine in the 
nineteenth and twentieth centuries” (Jackson, 2011). In Western Europe, between 1883 
and 1911, countries also passed national health insurance legislation, and shortly 
thereafter, there were regulations for food and drugs in the medical market (Jackson, 
2011). As time has continued into the present age, a medical field with more government 
regulations was more commonplace. In regards to the United States, Jackson (2011) 
writes that the U.S. has become dependent on “big science” to solve its health issues, 
possibly because the U.S. does not have a national health care system, and thus, health 
insurance companies have become a defining characteristic of American medicine.  
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The history of medicine is long and complex, and a few traditions of medicine 
have been left out to provide clarity and to provide a more relevant history of the Western 
tradition of medicine that is the backbone of the today’s tradition. Not every event in the 
history of medicine is still relevant today, but many themes are still relevant and have 
evolved into the practices that we are familiar with. These practices include treatments, 
scientific research, and patient-care. Thus, it is the medical practices of today that have 
sparked my interest in the field and that made me want to become a physician.  
Looking back, I cannot pinpoint the exact moment that I wanted to become a 
physician. Rather, it was a succession of events that ultimately led me to the path that I 
am on today. One of those major events was the day my nephew, Ethan, was born. Ethan 
was born with a rare genetic disorder known as urea cycle disorder; he was diagnosed 
within 48 hours of being born. Only 15 at the time, I could have never predicted the 
impact that Ethan would ultimately have on my life. At 3 months old, he received a liver 
transplant from UCLA Ronald Regan Medical Center. Although there were other health 
complications along the way, today, he is healthy and as rambunctious as any 5 year old 
can get. 
 He is ultimately my inspiration for becoming a physician. I aspire to be like one 
of the physicians on the amazing team of physicians that provided Ethan with the best 
possible care as they were able to perform under dire circumstances. At all times, they 
remained calm and composed and were able to provide the best possible care for Ethan. 
Ultimately, that is what physicians should aim to do. Physicians should provide the best 
possible care even under unforeseen circumstances. This belief has been furthered 
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solidified by my time spent volunteering in an Emergency Department (ED) in Denver, 
Colorado. I saw the physicians providing care in a stressful environment to the best of 
their abilities. Often times, the patients are difficult and can be stubborn, which is 
expected. Patients are scared coming into the ED. Often, they do not want to be there and 
the long waiting time just adds to the anxiety they may already be feeling. Regardless, the 
doctors are expected to provide their patients with exceptional care.  
Reflecting on these experiences, I began to consider what goes into “exceptional 
care.” Does providing the best care only encompass achieving desirable results like a 
successful liver transplant? Or is writing a prescription a sufficient requirement for 
exceptional care? How much time does a physician need to evaluate, diagnose, and then 
treat a patient? It may seem obvious that this would require time; time that develops into 
a relationship with the patient, but is it even necessary for doctors to develop 
relationships with their patients? These thoughts led me into contemplating what it even 
means to be a physician and what his/her roles and duties are to his/her patients.  
It became clear to me that the physicians who treated my nephew and those who 
work in my ED are practicing care that is ideal, and that care may not the standard but 
rather the exception. Doctor-patient relationships are becoming compromised in today’s 
society, and I will be examining one particular issue that is compromising that 
relationship. Dr. Abramson, a retired family physician sheds light on this issue: 
The pressure from my patients to prescribe Celebrex and Vioxx did not let up, 
intruding into alliances that had been built up over many years. I tried to explain 
that these drugs offered no better relief than the older, less expensive anti-
inflammatory drugs. I actually started to enjoy the challenge of trying to refocus 
my patients’ attention back onto their underlying issues…I did my best to help 
them understand that their beliefs about these drugs were being masterfully 
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manipulated by the companies’ multipronged marketing efforts, and that these 
efforts were being driven far more by the goal of improving the drug companies’ 
sales than improving patients’ health or comfort. (Abramson, 2004)  
 
Dr. Abramson was a physician for 28 years before he left his practice to write his book, 
Overdo$ed America. It tells of the new reality in American medicine; a reality in which 
television, magazine, and print advertisements of prescription drugs permeate our 
everyday lives. Those advertisements are known as direct-to-consumer drug 
advertisements, or DTC advertisements. The Federal Drug Administration (FDA) defines 
direct-to-consumer advertisements as “ads [that] are published in magazines and 
newspapers that are distributed to a general audience rather than to healthcare providers 
such as doctors, nurses, and pharmacists. DTC ads can also be broadcast through 
television or radio” (Drug Advertising: A Glossary of Terms, 2016), and huge amounts of 
money are being spent on DTC advertisements. Drug companies spent $4.5 billion on 
prescription drug TV advertisements (Millman, 2015). With that much money being 
poured into these advertisements, one has to wonder if the pharmaceutical companies 
have the patients’ best interest at heart. The patients may not realize that their care can be 
compromised when there is an overload of drug advertisements giving them insight as to 
how physicians should provide care. They may not realize that the drugs being advertised 
are being advertised not in the best interest of the patients but in the best interest of the 
drug companies.  
In today’s world, it is nearly impossible to go anywhere or do anything without 
seeing an advertisement. Whether it is for clothes, makeup, or even drugs, they are 
everywhere, and it is very difficult to deny the influence that these advertisements have in 
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our everyday lives. Patients consume the information from the advertisements, and then 
go to their doctor with the information they received. However, not every advertisement 
applies to every patient. Doctors have to be able to communicate that not every drug-
related treatment their patients see is going to be effective for whatever problem is being 
addressed. Thus, the doctor-patient relationship can be strained if the patient insists on 
having that particular drug. It then becomes essential for physicians to evaluate how to 
maintain their relationships with patients with the influence of drug advertisements, and 
in those situations, it becomes crucial for them to remember what it means to be a 
physician.  
In my attempt to determine how drug advertisements are affecting doctor-patient 
relationships specifically, I will be analyzing, first, what it means to be a physician 
providing the best possible care. I will discuss physicians’ roles and duties to their 
patients. To aid in this discussion, I will analyze the modern Hippocratic oath that many 
physicians recite today after completing their medical education. The oath provides an 
ethical outline as to how physicians should care for their patients and gives a more 
concrete understanding of the doctor-patient relationship. Once the role of the physician 
is fully understood, I can discuss how DTC advertisements are affecting doctor-patient 
relationships. After analyzing drug advertisements in today’s society, I will then discuss 
what direct-to-consumer drug advertising might look like as medicine begins to evolve 
towards personalized medicine and determine how doctor-patient relationships might also 
evolve with personalized medicine. Although the overwhelming amount of drug 
advertisements in today’s society leads some patients to better communicate with their 
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physicians, that communication does not lead to an improvement of the care the patient 
receives. Furthermore, those advertisements are resulting in skyrocketing drug prices and 
the inability for physicians to provide adequate care to their patients. Therefore, it is 
imperative that prescription drug advertisements be removed altogether or have limited 
availability to the general public. It is in the best interest of pharmaceutical companies 
and physicians to continue to put patient care and overall public health as priority. 
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II. Role of the Physician 
The issue of drug advertisements brings up fundamental questions on what it 
means to be a doctor. Before I begin a discussion on how drug advertisements influence 
the care that doctors administer, it is important to begin with what physicians’ roles are in 
the first place. There are different components to being a physician, and years of training 
are required. However, I will focus specifically on the role of the physician as it is related 
to diagnoses and treatments. It is ultimately how physicians develop relationships with 
their patients that will influence the diagnoses and treatments of those patients. Doctors 
must be compassionate, caring, understanding, and listen openly to their patients. 
Although developing these qualities and acting on them is at the discretion of the 
individual physician, there is an oath, or a variation of, that all doctors take at the end of 
their medical education that can serve as a guideline. The most widely used and well-
known oath is the Hippocratic oath.  
  The original Hippocratic oath written by Hippocrates himself, is rarely used 
today. Instead, the modern oath was written by Louis Lasagna, the then academic dean at 
Johns Hopkins University, in 1964 (Eva, 2014). The modern Hippocratic Oath is as 
follows: 
I swear to fulfill, to the best of my ability and judgment, this covenant: 
I will respect the hard-won scientific gains of those physicians in whose steps I 
walk, and gladly share such knowledge as is mine with those who are to follow. 
I will apply, for the benefit of the sick, all measures which are required, avoiding 
those twin traps of overtreatment and therapeutic nihilism. 
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I will remember that there is art to medicine as well as science, and that warmth, 
sympathy, and understanding may outweigh the surgeon's knife or the chemist's 
drug. 
I will not be ashamed to say "I know not," nor will I fail to call in my colleagues 
when the skills of another are needed for a patient's recovery. 
I will respect the privacy of my patients, for their problems are not disclosed to 
me that the world may know. Most especially must I tread with care in matters of 
life and death. Above all, I must not play at God. 
I will remember that I do not treat a fever chart, a cancerous growth, but a sick 
human being, whose illness may affect the person's family and economic stability. 
My responsibility includes these related problems, if I am to care adequately for 
the sick. 
I will prevent disease whenever I can, for prevention is preferable to cure. 
I will remember that I remain a member of society, with special obligations to all 
my fellow human beings, those sound of mind and body as well as the infirm. 
If I do not violate this oath, may I enjoy life and art, respected while I live and 
remembered with affection thereafter. May I always act so as to preserve the 
finest traditions of my calling and may I long experience the joy of healing those 
who seek my help. (“Hippocratic Oath”, 2004)  
 
The oath touches on many prevalent aspects of today’s healthcare, but I will only analyze 
those lines in which patient care is applicable. The first line I wish to look at states, “I 
will apply, for the benefit of the sick, all measures which are required, avoiding those 
twin traps of overtreatment and therapeutic nihilism.” Overtreatment is the overuse of 
therapy, drugs, and psychotherapy. Therapeutic nihilism is exactly the opposite. It refers 
to undertreatment (Mamede & Schmidt, 2014). That is, the body should be able to heal 
on its own. Essentially, the oath is stating that there has to be proper balance of how a 
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patient is cared for. Letting the body heal on its own is not always the best or the most 
responsible mode of action, but overtreatment is just as harmful to the patient. 
In regards to the relationship with the patient, the oath states, “I will remember 
that there is art to medicine as well as science, and that warmth, sympathy, and 
understanding may outweigh the surgeon’s knife or the chemist’s drug.” This line implies 
that there is a humanistic approach to medicine. Moving beyond science, “warmth, 
sympathy, and understanding” are necessary qualities for a doctor to have. Thus, it is 
emphasizing that caring for patients and treating them in a humanistic way is more 
important than the science of medicine. Patients are more than just bodies to practice 
surgeries on or to supply with drugs; they are people who should be treated as such. 
Treating people with warmth and understanding goes beyond solely trying to treat them. 
In fact, if treating a patient is actually degrading to who he/she is as person, then 
treatment should be avoided altogether.   
The aforementioned line plays directly into the lines, “I will remember that I do 
not treat a fever chart, or a cancerous growth, but a sick human being, whose illness may 
affect the person’s family and economic stability. My responsibility includes these related 
problems, if I am to care adequately for the sick.” Caring for a patient extends beyond the 
illness itself. Physicians are treating “a sick human being” which implies that there is a 
certain standard to how they should be treated. Stating that humans are more than their 
illnesses shows a certain respect for not only their bodies but also their humanities. 
Furthermore, by stating that the patient’s illness could affect not only his/her family but 
its economy as well, implies that the physician is involved in something larger. Anything 
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the physician does has implications for the wider community. Therefore, it is necessary 
for physicians to think carefully about how they treat their patients and the larger impact 
on the patients, their families, and the greater society. If doctors can remember to do this, 
then they will be able to treat their patients not only with the appropriate treatments but 
also with a respect and dignity that all persons deserve. Doctors go into their profession 
with the intentions of healing, but they must remember that it is not just what they are 
healing but whom they are healing, the latter superseding the former.  
The oath provides an ethical outline as to how physicians should provide care for 
their patients. It becomes evident that being a physician extends beyond the scope of 
scientific knowledge; it also involves a deep understanding of human nature (Hellín, 
2002). Being a doctor extends beyond just knowing the science behind the medicine; it is 
also about realizing that the medicine is being applied to real people and should be held 
to a higher standard. Doctors must possess a wide array of knowledge and be able to 
retain information correctly so as to be of the most use to their patients. It is the best 
doctors that can use the knowledge they possess to effectively care for their patients. 
However, they must also possess qualities that show that they are understanding of 
people and the situations that they are in. There will often be times when patients and 
physicians live drastically different lifestyles, but they have to be committed to patient 
care regardless of the patients’ lifestyle and value system (Hellín, 2002). Even if doctors 
themselves cannot relate to the situation their patients are in, they have to still show that 
they care and are willing to do what is necessary to improve the situation. Thus, doctors 
also have to be flexible, understanding, and fully committed to their patients. A physician 
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must provide care at all costs if it is in the best interest of the patient. Ultimately, the goal 
of the physician is to heal the patient with the understanding that the healing process 
encompasses being caring towards and having compassion for the patient. 
Establishing a foundation for how patient care should be administered is essential 
to providing quality diagnoses and treatment. The first of the two, diagnoses, begins the 
process of effective treatment (Taylor, 2015). Diagnosis is defined as “the elucidation of 
the cause of heretofore unexplained symptoms, signs, and laboratory/imaging findings” 
(Taylor, 2015). Learning to diagnose is a skill that requires a significant amount of 
medical knowledge and learning how to apply that medical knowledge on a case-by-case 
basis. In order to be successful at that skill, a physician must also have a good memory, 
excel at physical examinations, and be an empathetic listener (Taylor, 2015). Of these 
skills, being an empathetic listener is perhaps one of the most important qualities. 
Patients are often more willing to disclose information to physicians they feel more 
comfortable with. It is through listening that a patient’s current problem is discovered. 
Combined with the patient’s medical history, an accurate diagnosis is dependent on there 
being an intimate relationship between the physician and the patient because the doctors 
must know a great deal of information about their patients and about their values (Hellín, 
2002). That relationship develops as patients begin to feel more comfortable with their 
doctors, and they can begin to feel more comfortable with their doctor if they exhibit the 
aforementioned qualities. Furthermore, if there is an increased capacity for 
communication between the doctor and the patient, the strength of the doctor-patient 
relationship increases as well as the strength of the diagnosis.  
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Therefore, communication is essential to the development of doctor-patient 
relationship and leads to the most accurate diagnosis. Moreover, utilizing effective 
communication skills is becoming increasingly important when delivering the diagnosis 
itself. More than ever, there is an emphasis on full disclosure and communication skills in 
the medical field (Sisk et al., 2015). The American Hospital Association created “A 
Patient’s Bill of Rights” in 1973, and from then on, patients have the right to know every 
aspect of their health and medical care regardless of severity (Sisk et al., 2015). Thus, 
knowing how to properly communicate about a diagnosis to a patient is becoming 
increasingly important. Of course, this is a challenging skill to learn and one that often 
improves over time, but it is essential to the discovery and the communicating of a 
diagnosis and then ultimately how a physician will treat said diagnosis.  
Once a proper diagnosis is given, the physician can provide the best treatment. 
There are a myriad of treatments available, but the appropriate treatment must be 
administered for the given diagnosis. Many treatments today are administered according 
to science-based medicine and clinical guidelines (Taylor, 2015). However, it is possible 
that clinical guidelines can disagree, and while remaining aware of clinical guidelines is 
important, it is important to treat patients based on “evidence, experience, and clinical 
context” (Taylor, 2015). This means that the physician has to be knowledgeable about the 
current treatments available and consider any alternatives that might serve the patient 
better. When new treatments become available, physicians must also be knowledgeable 
about those as well. The physicians have to understand how the drugs work and their 
implications for patients. Each patient could potentially respond differently to different 
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drugs, and therefore, each patient might need a different treatment even if he/she have the 
same disease. The physician’s full understanding of the drugs will help eliminate any 
unwanted side effects and mitigate any risks (Taylor, 2015). Thus, there are several 
important components that go into administering effective treatments. 
Diagnosis and treatment are two crucial components of a physician’s duties. The 
oath sets a standard for the practice of medicine that can be utilized when giving 
diagnoses and treatments. However, utilizing this oath in everyday situations becomes 
more complicated as the medical field itself gets more complicated. In theory, doctors 
should consider the Hippocratic oath everyday in their communication with and treatment 
of patients, but it will become clear in the next chapters that the principles of the oath can 
be forgotten in certain situations. It will become evident that the oath and the 
development of the doctor-patient relationships can shift when new complications, such 
as DTC advertisements, come into play.  
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III. A Brief History of Drug Marketing 
Now that the role of the physician has been established, I can analyze how DTC 
advertisements can complicate that role. However, before discussing the drug 
advertisements of today, it is necessary to give a brief history on how they came to be in 
the first place. Much of the history of drug advertisements is connected with the FDA 
because it has largely controlled the regulation of drug advertisements. The FDA is 
responsible for many aspects regulating public health in the United States, including the 
safety of food, cosmetics, and medications among others. With regards to medications, 
the FDA is “responsible for advancing the public health by helping to speed innovations 
that make medicines more effective, safer, and more affordable and by helping the public 
get the accurate, science-based information they need to use medicines and foods to 
maintain and improve their health” (Federal Drug Administration, 2016). Because the 
FDA is responsible for regulating prescription drugs, it soon became responsible for 
regulating the advertisements of prescription drugs. 
The regulation of prescription drugs began in 1906 with the Federal Food, Drug, 
and Cosmetic Act. The goal of the act was to provide consumers with the information 
about the effectiveness of certain medicines. The act was expanded in 1938 and again in 
1962. It was in 1938 that proving the safety and effectiveness of drugs before they could 
be put on the market began. Prior to the provisions of this act and not until after World 
War II in 1945, self-medication, that did not have any scientific backing, was a popular 
practice. It was popular even more so than today because people were not seeking 
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pharmacological treatment as prevalently. Instead, prior to World War II, people were 
likely to self-medicate based off of unsubstantiated claims frequently found in newspaper 
advertisements. An example can be seen in an advertisement for cocaine toothache drops 
(Figure 3). The advertisement claims that the drops are an instantaneous cure, and people 
could obtain them without knowing if they actually worked and without 
recommendations from a physician. Shortly thereafter, drugs could only be obtained after 
a physician wrote a prescription. As a result, pharmaceutical companies began to 
advertise their products directly to physicians (Donohue, 2006).  Prescription drug 
advertising was largely under the control of the Federal Trade Commission (FTC) prior 
to 1962, but in 1962, the FDA was granted jurisdiction over DTC advertisements 
(Donohue, 2006; Frosch et al., 2010). 
 
Figure 3. Example of a drug advertisement prior to the enactment of the Federal Food, 
Drug, and Cosmetic Act in 1906 (Say Yes to Drugs?, 2014).  
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Final guidelines for drug advertising were issued in 1969. The advertisements: 1.) could 
not contain any information that was considered false or misleading, 2.) could contain a 
“fair balance” of the risks and of the benefits of using the drug, 3.) could present facts 
that are essential to the advertised uses of the drug, and 4.) must contain a summary of 
the risks involved with taking the drug (Boden & Diamond, 2008). The provisions, 
however, made no mention of advertising to the public (Donohue, 2006). The FDA does, 
in fact, provide an explanation as to why.  
According to the FDA, there had been no necessary federal ban on DTC 
advertising because drug companies provided information about their products directly to 
doctors and pharmacists. They did this through medical journals, continuing medical 
education, sales calls, etc. (Abramson, 2004). It was not until the 1980s that some drug 
companies began providing more information about drugs to the general public, rather 
than to physicians, through advertisements (Background on Drug Advertising, 2015). In 
1981, drug companies began advertising directly to the public and bypassing physicians. 
The first print drug advertisement was published in Reader’s Digest by the company, 
Merck, that was advertising a new antipneumococcal vaccine (Ventola, 2011). Not long 
after, the first broadcast advertisement and print advertisements were put out by Boots 
pharmaceuticals to promote a prescription pain reliever, Rufen (Donohue, 2006). Boots 
was promoting a lower price of their version of ibuprofen as compared to Motrin, which 
was produced by McNeil Consumer (Figure 4) (Ventola, 2011).  
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Figure 4. Screen grabs from the first broadcasted drug advertisement by Boots pharmaceuticals 
promoting their product, Rufen, a pain relieve (Scott, 2015).  
As a result of these advertisements, the FDA was forced to review its policies. In 1985, 
the FDA came to the conclusion that the these new drug advertisements would have to 
follow the same stipulations, such as the fair balance of both risks and benefits and the 
brief summary of potential side effects, which are outlined in the 1969 addendum to the 
Federal Food, Drug, and Cosmetic Act. Because of these stipulations, drug 
advertisements in the 1980s were largely print advertisements as the airtime was not long 
enough to include all of the necessary information as required by the FDA (Ventola, 
2011). Drug companies, clearly not satisfied with these restrictions, applied pressure on 
the FDA to loose some of the restrictions (Abramson, 2004).  
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 In order to address the dissatisfaction expressed by the pharmaceutical companies, 
the FDA held hearings in 1995 to discuss the regulations and potentially loosen its 
restrictions (Ventola, 2011). Pressure from the pharmaceutical companies forced the FDA 
to introduce new provisions for broadcasted advertisements in 1997 (Donohue, 2006). 
The advertisements no longer had to include a brief summary of the side effects; they 
only needed to include “major risks” and directives, such as a toll-free number, a print ad, 
a website, or a physician, for consumers to access the entire summary of potential side 
effects (Donohue, 2006; Ventola, 2011). Pharmaceutical companies quickly responded to 
these new policy changes, nearly doubling their spending on television advertisements. 
The amount of money invested into television drug advertisements climbed from $310 to 
$664 million between 1997 and 1998. By 1998, the total amount of money spent on all 
drug advertisements reached $1.3 billion. A majority of all spending for DTC 
advertisements transitioned to television advertising after the policy changes, and the 
1990s saw nearly 80 percent of prescription drug advertisements focus on the drug itself 
rather than the medical condition (Donohue, 2006). The changes that took place resulted 
in a shift where pharmaceutical companies took the place of the physicians’ diagnoses 
and treatment choices.  
 From the aforementioned statement, it could be argued that patients are 
consumers, and in fact, they are. However, should prescription drugs that treat serious 
illnesses be advertised in the same light as groceries? As was discussed earlier, “A 
Patients’ Bill of Rights’ was created in 1979. Patients have the right to full disclosure in 
regards to their healthcare, but it begins to get complicated when the patient becomes the 
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consumer. Where is the distinction made and what implications does it have in regards to 
drug advertisements? As was mentioned earlier, the 1990s saw a dramatic increase in the 
amount of information made available to patients. Not only was this information made 
available through televised advertisements, but also through the increase in technology, 
such as the use of personal computers and increased access to the Internet. Those gave 
patients access to a lot more information in regards to their healthcare and 
consequentially medical decision-making. It was also shown that in 1990, only about 
one-quarter of Americans felt confident with medical leaders as opposed to three-quarters 
in 1966 (Donohue, 2006). With this decline in trust and the increasing availability of 
information, it was inevitable that patients would begin to become more involved with 
their healthcare. It must be made clear that patients being involved in their healthcare are 
not the issue. The issue stems from DTC advertisements exploiting the changes that were 
occurring during this time, and any criticism of the advertisements was being ignored. It 
is evident that the amount of information made available to the patients along with 
expanding trend of patients becoming more involved in their care was responsible for the 
increasing amount of drug advertisements. The industry now invests billions of dollars 
into drug advertisements, and the criticisms of those advertisements are no longer being 
ignored. Critics of DTC advertisements come from physicians, consumers, and even 
some in the pharmaceutical industry (Donohue, 2006). There are concerns with whether 
or not the facts presented in the advertisements are actually beneficial to the patient and 
whether or not they are misleading patients. The advertisements have the potential to 
discredit physicians if physicians choose to not prescribe the advertised drugs. This could 
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be detrimental to physician-patient relationships and to the medical field as whole. 
Therefore, it is necessary to analyze how DTC advertisements have changed the 
healthcare industry, in what ways, and if there are any necessary changes that need to be 
made.  
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IV. Drug Advertisements Today 
It seems as if everywhere we look, there is a new drug that is being advertised. What 
are doctors’ moral obligations in providing the patient the best care they can while also 
dealing with outside sources essentially telling them how to treat their patients? How are 
doctors to respond to patients who insist on being prescribed a certain drug even if it is 
not in their best interest? Furthermore, if doctors do prescribe those medications, do they 
have some ethical obligation to ensure that their patients receive those medications 
despite their increasing costs?  
Before addressing the physician’s responsibility and DTC advertisements, the current 
FDA regulations on prescription drug advertisements need to be discussed. The 
regulations that were established in 1997 were not revisited until 2004 when the drug 
Vioxx, nonsteroidal anti-inflammatory drug (NSAID) used to treat arthritis, acute pain, 
and painful menstrual cycles was voluntary removed from the market (Frosch et al., 
2010; Federal Drug Administration, 2004). Vioxx was one of the most advertised drugs 
in the United States from 1999 to 2004. The company that promoted the drug, Merck, 
spent nearly $100 billion promoting it, with nearly $1 billion in revenue (Ventola, 2011). 
In fact, Vioxx received Brand of the Year in 2001 as a result of the success of its 
advertising (Jaramillo, 2006). However, it was later found that Vioxx was linked to an 
increased risk of developing cardiovascular disease, and as a result, the drug was pulled 
from the market in 2004. Despite this, in 2004, the FDA again loosened regulations on 
DTC advertisements allowing print advertisements to only include a brief summary of the 
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product rather than the complete prescribing information (Ventola, 2011). This led the 
U.S. Senate leader in 2005, physician William Frist, to call for a two-year voluntary 
moratorium on DTC advertisements for newly approved drugs (Donohue, 2006). The 
purpose of the moratorium was to delay the time newly approved drugs were advertised 
directly to consumers to allow physicians time to understand the purpose of the drugs 
before they begin prescribing them to patients (Saul, 2005). In response to the proposed 
moratorium, some pharmaceutical companies announced a voluntary moratorium, and 
Pharmaceutical Research and Manufacturers of America (PhRMA), the pharmaceutical 
manufacturers trade group, proposed suggested guidelines that companies could adhere to 
with DTC advertisements. However, those guidelines were strictly voluntary, and it is not 
obvious whether or not the companies have adhered to the moratorium. Ultimately, no 
government regulations were put in place in regards to the moratorium (Ventola, 2011). 
Perhaps, this is why there was not a decrease in the amount of money being spent on drug 
advertisements after 2005 (Figure 5). In fact, as the amount of spending on DTC 
advertisements increased, FDA enforcement of regulations regarding DTC 
advertisements decreased (Figure 5). Several reasons are cited for this decrease, but the 
two main reasons are the same amount of staff remain to review the drug advertisements, 
despite the increase in number, and the FDA is underfunded (Ventola, 2011).  
However, there was a decrease in spending of DTC advertisements from 2007 to 
2008 because of the financial crisis that caused the economy to slow down, causing the 
first significant decrease in spending since 1998 (Figure 5) (Ventola, 2011). There was 
renewed interest on the issue in 2007 and again in 2009, but legislators failed to reach a 
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consensus on DTC advertisements, and thus, it remains a polarized issue (Frosch et al., 
2010). The FDA plays a critical role in the regulation of DTC advertisements, but if it is 
failing to enforce regulations, patients are at risk of receiving misleading information. 
Legislators cannot adequately address the issue because it is such a divisive debate.  
 
 
Figure 5. Top figure shows the amount of spending in billions  on drug advertisements from 1998 
to 2009. Bottom shows FDA enforcement of regulations regarding DTC advertisments. As 
spending on drug advertisements increase, FDA enforcement decreases (Ventola, 2011).  
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To provide clarity as to why DTC advertisements are so divisive, the positive and 
negative components of DTC advertisements needs to be discussed. As can be seen in 
Figure 6, Frosch et al. (2010) suggests that there is a conceptual framework that exposure 
to DTC advertisements follows. When people are exposed to DTC advertisements, that 
leads to prescription requests based off a variety of factors, including the age of the 
consumer, gender, education, and medical history. However, the information in the 
advertisements can be of either high or low quality, but regardless of the quality of 
information, it results in clinical care.  
 
Figure 6. A model showing the effects of DTC advertisements (Frosch et al., 2010). 
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This is considered a positive effect, but one of the results is inappropriate prescribing i.e. 
prescribing medications when it is unnecssary (Figure 6) (Frosch et al., 2010). The other 
two outcomes: adherence to prescribed regimen and amelioration of undertreatment can 
be seen as positive outcomes, but those outcomes are very dependent of the quality of 
information presented in the advertisements, and the quality of the information presented 
is part of the controversy. Thus, the end result of that exposure can vary depending on the 
type of information patients receive.   
First, I will discuss the arguments that supporters of DTC advertisements pose. 
Some of those arguments include, but are not limited to, informs the patient, encourages 
the patient to contact their physician, promotes patient-physician communication, 
strengthens the patient-physician relationship, increases treatment for under-diagnosed 
conditions, and reduces stigma associated with certain diseases (Ventola, 2011). Perhaps, 
the most widespread argument for the use of DTC advertisements is that they inform and 
educate the patients. According to Frosch et al. (2010), surveys have been administered to 
patients and physicians, and more than half of physicians claim that DTC advertisements 
have the potential to educate patients about various health conditions and treatments. In 
regards to the public, 75% of respondents claimed they had an improved understanding of 
various diseases and treatments, and 40% reported that they used the DTC advertisements 
to guide their decisions regarding treatment regimens (Frosch et al., 2010). Furthermore, 
proponents of DTC advertisements claim that the advertisements encourage patients to 
visit their physician thereby increasing physician-patient communication and 
strengthening the physician-patient relationship (Ross & Kravitz, 2013). 
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Along with increased communication between physicians and their patients, 
proponents of DTC advertisements claim that patients are more likely to follow their 
prescription regime (Figure 6). The likelihood they will follow their prescription regime 
is because the drug advertisements for the drugs they are taking will serve as reminders 
(Ross & Kravitz, 2013). However, data for this is scarce or has mixed outcomes. For 
example, Frosch et al. (2010) discuss a survey, nationally representative of the public, in 
which 82% of respondents believed that the drug advertisements could help them follow 
the physicians’ guidelines for the prescriptions, but only 23% of patients recruited in 
waiting rooms said the advertisements would increase the likelihood of them taking the 
drugs. Proponents also argue that drug advertisements are making patients more aware of 
illnesses that could have gone unidentified and untreated (Royne & Myers, 2008). Thus, 
it can be said that proponents of DTC advertisements believe the educational value of the 
advertisements far outweighs any potential risks associated with the advertisements. 
However, the opponents of DTC advertisements have various reasons as to why the risks 
associated with DTC advertisements far outweigh any potential educational value.     
The arguments against DTC advertisements directly counteract the arguments 
made in support of them. Opponents of DTC advertisements believe that they interfere 
with physician-patient relationships, increase the cost of medications, oversimplify 
complex medical issues, and promotes the use of newer products over older, safer, and 
cheaper alternatives (Kaphingst & Dejong, 2004). In regards to the physician-patient 
relationship, there are physicians who feel that the advertisements lead to patients making 
unnecessary, and even unwarranted, requests (Frosch et al., 2010). However, the 
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evidence on the effects of DTC advertisements on physician-patient relationships is 
conflicted. Frosch et al. (2010), report that 39% of physicians and 30% of patients 
believed the advertisements had a negative effect on the physician-patient relationship 
while an industry-funded survey found that 82% of physicians did not associate 
physician-patient problems with DTC advertisement. However, in yet another survey, 
89% of family physicians did not believe that DTC advertisements benefitted their 
relationships with their patients. In fact, physicians are more likely to report negative 
aspects of DTC advertisements than patients are because the advertisements promote 
unnecessary medical visits and prescription requests. Despite this, one survey found that 
up to 78% of prescription requests were filled thus leading to inappropriate prescribing 
acts (Frosch et al., 2010). Not only is there inappropriate prescribing acts, but there is 
also an increase in prescribing acts altogether (Ross & Kravitz, 2013). This cause an 
overall increase in healthcare costs for the patient (Direct-to-consumer advertising under 
fire, 2009). Thus, there is the question of whether or not the DTC advertisements are 
actually benefitting the patients. 
There are inherent risks involved when taking any medication, but if patients are 
being prescribed drugs that are medically unnecessary, are they fully aware of the risks 
involved? The answer to that question appears to be mixed. O’Donoghue et al. (2013) 
state that the advertisements themselves do not have or have very little information in 
regards to drug efficacy, and even if they do, patients have a difficult time understanding 
that information or overestimate the efficacy of the drug. Kaphingst & Dejong (2004) 
conducted a study in which participants were asked to answer true/false questions 
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regarding the drug advertisements they had been shown. The authors found that the 
chances of the participants answering correctly was lower when the questions involved 
risk information as opposed to other information presented in the advertisement. 
Furthermore, there was a lower chance of answering correctly if the information was 
given in text, both with and without audio, as opposed to just audio. Therefore, it seems 
that patients have the most difficulty comprehending the risks associated with advertised 
drugs.  
Lastly, another argument against DTC advertisements is that they result in 
medicalization. Frosch et al. (2010) define medicalization as “the process by which 
nonmedical problems come to be defined as treatable illnesses, thereby potentially 
increasing unwarranted diagnoses.” Scholars argue that medicalization has resulted from 
mass marketing and that the pharmaceutical industry has been the major driving force 
behind medicalization. There is an argument that medicalization is actually beneficial in 
that it reduces stigma around certain illnesses, but critics maintain that the boundaries 
around illnesses are only widened to expand the drug market rather than improving health 
(Frosch et al., 2010; Payton & Thoits, 2011). The process of medicalization may have 
been an unforeseen consequence of DTC advertisements, but evidence regarding the 
potential social benefits of the process is scarce.  
The benefits and risks of DTC advertisements can be made more evident by using 
drugs that are currently on the market as examples. It can help to begin with Humira. 
Humira is a medicine that affects the immune system. It is a Tumor Necrosis Factor 
(TNF) blocker that can be used to treat a variety of autoimmune conditions, including but 
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not limited to rheumatoid arthritis, plaque psoriasis, and Crohn’s disease (Medication 
Guide HUMIRA®, n.d.). Because of its capability to treat a variety of diseases, AbbVie 
Inc., the company that makes Humira, spent nearly $357 million on advertising for this 
product in 2015, which was the largest amount spent that year, and this made Humira one 
of the most advertised drugs in the United States (Robbins, 2016a). The timing of the 
large amount of spending on advertising is not surprising because the patent on Humira 
will expire on December 31, 2016. When patents are set to expire, pharmaceutical 
companies will raise the prices of the drugs in order to gain as much revenue as they can 
before the patent expires. With the patent expiring, generic drugs can now be produced 
and would often cost less than the brand name drug. However, the new generic drugs that 
are produced in place of Humira will likely cost just as much as Humira did before the 
costs of the drug began increasing because the companies that produce the generic drugs 
will price the drugs just below the name-brand drug (which has been increased) (Rockoff, 
2016).  
 The advertisement itself may seem harmless to those who view it. One current 
advertisement shows a middle-aged woman packing and traveling to visit her family. The 
voiceover claims, “This is Humira helping me go further” (Figure 7). What viewers do 
not know is that this particular advertisement, known as “Go Further”, generated an 
estimated $9.4 million in revenue for AbbVie (Bulik, 2016). This advertisement is only 
one of 9 advertisements for the drug, but the other advertisements are targeted for a 
variety of other diseases. This particular advertisement includes everything that is 
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required by the FDA. It includes major side effects and a directive to visit another source: 
a website and instructions to discuss Humira with a physician.  
 
Figure 7. Advertisement for Humira (Bulik, 2016). 
 
The website is displayed in white writing on a purple block across the bottom of the 
advertisement throughout the duration of the advertisement; though, the size of the 
website pales in comparison to the figures in the advertisement themselves. The major 
side effects are spoken rather than listed like the website, but the side effects are not 
displayed in the advertisement. This practice is not optimal as it is not always the easiest 
way for people to retain information. For Humira, those side effects are lengthy and can 
be very serious. They can include allergic reactions, blood and liver problems, and even 
psoriasis (Medication Guide HUMIRA®, n.d.). Yes, the drug that advertises its 
effectiveness in treating psoriasis can result in psoriasis for patients who have never had 
it or worsen the condition for those who were previously diagnosed with the condition. 
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The advertisement also briefly displays that financial help can be given to those who may 
not be able to afford the medication, but there is never any mention about how much it 
costs, without or without insurance. If Humira is such an essential drug for many 
Americans, why is there a need to advertise in it the first place? Would doctors not want 
to prescribe the drug in the first place?  
Although makers of Humira spend the most amount of money advertising the 
drug, Humira is not a drug that most Americans need. Perhaps that is why more money is 
spent advertising it. Another health issue that affects many Americans is high cholesterol 
levels and the various diseases associated with it. A study conducted by Niederdeppe et 
al. (2013) found that DTC advertisements resulted in over-diagnosis of high cholesterol 
and consequentially over-treatment of high cholesterol. The study collected data using a 
nationally representative survey between 2001 and 2007. Questions from the survey 
included TV viewing habits, cholesterol diagnosis, statin (HMG-CoA reductase 
inhibitors) use, and other risk factors for coronary heart disease. Statins can block the 
build up of cholesterol in the liver, reduce LDL cholesterol (a main cause of coronary 
heart disease (CHD)), and reduce the risk of CHD. The authors also collected data on the 
advertisements themselves.  
The results from the study showed a positive association between DTC 
advertisements, high cholesterol diagnoses, and statin use. The results were consistent for 
both men and women. The authors make it clear that individuals who were at a relatively 
low risk for future cardiac events primarily drove the results, and there were very little 
positive associations between the DTC advertisements and those individuals at a 
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moderate or high risk for future cardiac events (Niederdeppe et al., 2013). Furthermore, 
there were negative associations between the advertisements and women diagnosed with 
coronary heart disease. Of course, there are limitations to the study, which the authors 
address, but overall, the results imply exposure to DTC advertisements results in a 
diagnosis from physicians of high cholesterol in individuals who are at a relatively low 
risk for future cardiac events. This, in turn, results in individuals taking statin drugs that 
are unnecessary.  
In 2011, Lipitor, a statin drug aimed at lowering cholesterol, became the highest 
selling drug in the world generating over $125 billion in sales over 14.5 years (Ennis, 
2011). That same year, the patent on Lipitor expired, which meant that generic versions 
of the medication could now be prescribed (Roan, 2011). Regardless of the brand name, 
statins are still being prescribed, despite some controversy. There is now evidence that 
statin use increases the risk of developing type-2 diabetes. In 2012, the FDA warned 
about these side effects and required the maker of Lipitor to include warnings about the 
diabetes risk. However, the warning labels were implemented too late for some people, 
and there is now a pending lawsuit against the maker of Lipitor (Lipitor Lawsuit: 
Litigation for Statin Drug Linked to Diabetes, n.d.). Despite the evidence of serious side 
effects and a lawsuit, there are doctors who are still prescribing statins and are receiving 
money to do so. A study conducted by Dejong et al. (2016) found that 279,699 physicians 
received 63, 524 payments, mainly in the form of meals, from the pharmaceutical drugs. 
Rosuvastatin, common brand for Crestor (a statin), represented 8.8% of statin 
prescriptions, and the authors found that those physicians who received one single meal 
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from the company promoting Rosuvastatin, prescribed Rosuvastatin more frequently than 
other statin drugs. Thus, there is another issue with doctors promoting certain drugs as 
well. If there is a shift from advertising more to the physician than to the patient, how 
should physicians respond accordingly?    
Although Lipitor is controversial, perhaps the most controversial drug currently 
on the market is the EpiPen. The EpiPen came to be in the 1970s by a request from the 
Pentagon because the Pentagon needed a way to deliver a nerve gas antidote. This drug 
could alleviate the allergic reaction caused by exposure to nerve gas. Thus, it would be an 
immediate defense for soldiers who were exposed to nerve gas (Reimann, 2016). The 
EpiPen was officially introduced in 1980 and is used in the general public to treat life-
threatening allergic reactions with epinephrine (Rubin, 2016). The drug company Mylan 
acquired the EpiPen in 2007, and at the time, only produced $200 million in revenue. 
However, as can be seen in Figure 8, EpiPen annual sales have increased dramatically 
(Koons & Langreth, 2015). Figure 8 shows the price increase through 2015. With the 
increase in sales came the dramatic increase in price, over a 400% price increase (Rubin, 
2016). The EpiPen itself only delivers about $1 worth epinephrine, but as of 2016, it cost 
$600 to purchase (Koons & Langreth 2015; Rubin, 2016). It only cost $57 when Mylan 
acquired the product in 2007. Koons & Langreth (2015) credit Mylan with utilizing 
textbook branding as well as a public awareness campaign. Those campaigns include 
television advertisements, but they differ from the previously discussed DTC 
advertisements.  
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Figure 8. Data from the first quarter of 2008 to the third quarter in 2015 showing an 
increase in the cost of EpiPen (Koons & Langreth, 2015).  
  
 These new advertisements are called “unbranded” advertisements. These 
particular advertisements inform the public about a medical condition and are paid for by 
a company who sells a drug for said medical condition. These ads are not required to 
disclose side effects; instead, they inform viewers to visit the website where they will 
learn about the treatment options the company offers (Robbins, 2016b). While the 
prevalence of these ads has varied, Mylan purchased nearly $15 million worth of airtime 
for an unbranded campaign it launched in April 2016 (Robbins, 2016b). Mylan capitalize 
with these advertisements because of the increased awareness of anaphylaxis reactions. In 
2010, there were new federal regulations requiring patients who experienced severe 
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allergic reactions to be prescribed two epinephrine doses. The FDA also changed label 
rules that allowed the EpiPen to be marketed to anyone at risk as opposed to those who 
had already experienced an anaphylaxis reaction (Koons & Langreth, 2015). As a result 
of these efforts, in part by Mylan, the use of the EpiPen has grown 67% in the last eight 
years (Koons & Langreth, 2015).  
 Mylan announced that it would release a generic EpiPen, but the price would still 
be $300 per pack of two (Rubin, 2016). Although the increase in cost for EpiPen was the 
result of different marketing tactics, the use of unbranded advertisements is a shift from 
traditional DTC advertisements. Despite informing the public about different medical 
conditions, they still direct people to websites that are sponsored by companies that sell 
the products. Even though there can be benefits to informing the public about certain 
medical conditions, patients should be aware as to who are the ones promoting those 
campaigns because the underlying message could be more about the specific treatment 
for the medical condition as opposed to the condition itself. Nonetheless, the use of 
advertisements to increase use of a specific drug does not seem to be slowing down 
because of the large profits companies receive, but it is interesting to note that DTC 
advertisements are not found worldwide.    
Currently, only the United States and New Zealand allow DTC advertising. The 
reasons for this vary, but Guessous and Dash (2015) state that DTC advertisements have 
pros and cons that are regulated differently in different countries. Furthermore, 
constitutional factors and patient and population safety considerations also play a role. In 
the United States, the First Amendment protects the right to free speech, including 
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commercial speech (Guessous & Dash, 2015). In New Zealand, unlike other developed 
countries, there was never any legislation that prevented the use of DTC advertisements. 
Similar to the United States, there were calls to ban DTC advertisements. The New 
Zealand government responded in 2003 calling for a complete ban on the advertisements, 
but the necessary legislation was not successfully passed (Toop & Mangin, 2007).  
Perhaps the biggest reason why there are different regulations regarding DTC 
advertisements is the lack of data surrounding them (Guessous & Dash, 2015). Most of 
the data published is based off of surveys and opinions rather than experimental evidence. 
The interpretations of the results can, therefore, be subjective. Thus, there are various 
reasons as to why other countries do not have DTC advertisements. 
While New Zealand has been unable to completely ban DTC advertisements, 
Europe has recently been looking to allow DTC advertisements. In 2002, the European 
parliament began debating about DTC advertisements except for ones that advertised 
drugs for diabetes, asthma, and AIDS. However, the proposal was rejected (Rutter & 
Gilbody, 2008). The debate then became prominent again in 2007, and the European 
Commission published a document that discusses the patients’ rights to information. This 
document is significant because it discusses the Internet as a different means of providing 
information. Indeed, the Internet user has to actively search for information before that 
information is available to them. The European Commission is trying to make a 
distinction between advertising and information (Velo & Moretti, 2008). This distinction 
was important for the European Commission proposal in 2008 that was aimed at trying to 
provide patients with “non-promotional” information (Rutter & Gilbody, 2008). A 
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majority of the European Commission voted against the proposal (Direct-to-consumer 
advertising under fire, 2009). Currently, the debate continues about whether or not to 
allow DTC advertisements, and if the ban is lifted, there will be intense consideration 
about what regulations will be in place and what those advertisements would look like.   
Europe is not alone in its consideration for allowing DTC advertisements. South 
Korea is also looking at allowing DTC advertising. Because of increased access to the 
Internet, more people are utilizing it to learn more about health information. As a result 
of the increased access to information, Suh et al. (2011) felt that it was necessary to 
survey South Koreans on their attitudes toward DTC advertisements. In South Korea, 
drug advertisements are regulated, but DTC advertisements for prescription drugs are 
generally prohibited with the exception of “professional” health journals and drugs that 
are considered a preventative measure for contagious diseases, such as AIDS, plague, and 
typhoid fever. The authors surveyed 350 subjects and addressed four different areas 
concerning DTC advertisements. Those are the consumers’ attitude towards DTC 
advertisements, consumer preferences regarding regulation, consumers’ expectation 
regarding the effects of the advertisements, and the types of credible advertisements. 
Although 52 respondents were excluded for incomplete questionnaires, 61.8% of those 
who responded felt that DTC advertisements were necessary, but only 43.3% felt that 
they could trust the information provided by the advertisement. Although the respondents 
felt that the advertisements could be potentially educational in regards to treatments and 
disease awareness, they also felt that the advertisements could lead to a misuse or overuse 
of the drug advertised. To conclude, the authors note that South Korea must take a 
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cautious approach when it begins to discuss DTC advertisements and whether or not they 
should be implemented.      
Whether a country is just beginning to consider allowing DTC advertisements or 
the issue has been debated for years, banning the advertisements is just as difficult and 
contested a process as allowing them in the first place. In regards to the United States, 
perhaps the biggest debate about whether or not the advertisements can be banned 
altogether is the right to free speech argument. Advertising is considered “commercial 
speech” and its protection under the First Amendment dates back to the 1970s 
(Shuchman, 2007). The Supreme Court developed criteria, known as the “Central Hudson 
Test,” to determine if a ban on commercial speech is allowed. The test determines 
whether advertising is misleading, if a ban advances government interest, and if that 
government interest can be reached by utilizing a less restrictive method like including a 
label. That is, if having a ban does not fall in line with government interest, then a ban is 
not necessary. One lawyer, who served as a chief counsel for the FDA from 2001 to 
2004, said that because a doctor needs to intervene in the process of a patient acquiring a 
prescription that, it alone should prevent any ban on DTC advertising. Furthermore, he 
says that the drugs also have to be approved by the FDA before they can be put on the 
market, and because of FDA approval, DTC advertisements should be allowed. However, 
serious adverse side effects of a drug can be potentially unknown before there is 
widespread use of the drug, and thus an advertising moratorium should be put in place to 
allow for post-marketing surveillance (Shuchman, 2007). However, as was mentioned 
earlier, it is very difficult for regulations to be put in place for a moratorium to exist. 
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Although there is a need for post-market surveillance, a complete ban on DTC 
advertisements is unlikely. Furthermore, some believe that if Congress does enact a ban 
and it is overturned, then future attempts to control regulations on DTC advertisements 
would fail (Shuchman, 2007). Any efforts to completely ban DTC advertisements would 
have to be well thought out in a way that does not violate the First Amendment. 
Ultimately, if there cannot be a complete removal of the advertisements themselves, then 
careful considerations must be made in regards to how the advertisements could be 
restructured in a way that eases opponents’ concerns.      
Those who have studied DTC advertisements have several recommendations as to 
how the advertisements can be improved. There have been suggestions to have an 
independent agency that reviews the advertisements, but Guessous & Dash (2015) note 
that the FDA already has an office that reviews and controls the content of the 
advertisements. Because the agency is not independent, it is unclear whether or not there 
is potential for interests to be corrupted. However, the FDA enforcement of their policies 
on DTC advertisements has decreased over time. Royne & Meyers (2008) state that a 
policy change in 2002 now requires the FDA to obtain legal approval in order to issue a 
warning letter. This policy change has slowed the review process, and consequentially, 
less letters were issued altogether. Perhaps, a separate office or more employees need to 
oversee that the advertisements are still in compliance after a certain time period has 
elapsed. Royne & Meyers (2008) also report that there were concerns with how the 
advertisements are reviewed in the first place. The FDA does not have a consistent way 
of prioritizing the advertisements nor are there any official standards for determining 
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which ads would likely cause the most harm. It is evident that the FDA needs to fix its 
review process in order to limit the number of advertisements that may contain false or 
misleading information. In addition, as was mentioned earlier, the FDA is very 
underfunded so there also needs to be steps taken in order to ensure that the FDA is 
receiving adequate funding. So how can the advertisements themselves be improved?  
There are several different ways in which DTC advertisements can be improved. One 
of those improvements has to do with providing more information about the risks 
associated with taking the drug. In a survey conducted by the FDA in 2002, 60% of 
respondents did not think that DTC advertisements provided satisfactory information 
about the risks (Royne & Meyers, 2008). Beyond just communicating the risks, 
advertisements could also communicate the efficacy of the drug. O’Donoghue et al. 
(2014) showed that adding efficacy information, especially quantitative information, 
about a drug in the DTC advertisements for both print and television potentially increased 
an individual’s knowledge of the drug. If the patients are more aware of the effectiveness 
of the drug they wish to take, they may be more likely to make more informed decisions 
in regards to the drug. Furthermore, the authors believe this could lead to improved 
patient-physician communication because patients are more aware of both the benefits 
and the risks and thus are more educated when talking to their physicians. This differs 
from current advertisements that only relay risks rapidly on television advertisements.  
In addition to balancing benefit and risk information, improvements need to be made 
on the way the information itself is presented. Information in television advertisements 
should be presented in “consumer-friendly” language (Kaphingst & DeJong, 2004). That 
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means that considerations must be made in regards to the literacy level of the recipients 
of the advertisements. In addition to consumer-friendly language for television 
advertisements, “plain language” should be used in print advertisements. The reading 
difficulty of the advertisements should be no higher than an eighth grade level, which is 
the reading level of the average American adult (Kaphingst & DeJong, 2004). So not only 
should DTC advertisements include more information in the first place, they should 
include information that is clear and easy to understand for patients with different 
education levels. This does not mean that the information presented will be less precise. 
Doctors have to find ways to present complex information in simple ways to their 
patients, and creators of drug advertisements should be challenged to do the same. 
Perhaps, by even working closely with physicians, creators of drug advertisements can 
find the best way to communicate the risks of a drug without compromising any specific 
and important information.    
Lastly, there are suggestions about the way in which the advertisements are presented 
can be improved. That is, the way medical conditions and the treatment for those medical 
conditions are portrayed can be improved. Guessous & Dash (2015) state that most DTC 
advertisements portray medical conditions and their treatments in a very superficial, 
perhaps even glamorous, way. A study conducted by Frosch et al. (2010) showed that 
advertisement narratives for treatments for cardiovascular disease shifted perceptions of 
the actual cause of the disease. Participants were led to believe that high cholesterol was 
primarily caused by hereditary factors, thus reducing the need for lifestyle change. The 
authors suggest that there needs to be more scrutiny about the narratives used to show the 
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effectiveness of the drugs. Frosch et al. (2010) claim that less time is spent on the risks of 
a drug while the benefits are discusses intermittently throughout the advertisement. Thus, 
there needs to be more information about the risks and the effectiveness of the drugs. In 
addition, Kapingst & DeJong (2004) suggest that the advertisements, if they are really 
there to educate consumers, should also provide information about symptoms and other 
risk factors for the advertised disease. Essentially, the advertisements should present 
more accurate depictions of what the disease looks like.   
A somewhat unconventional idea, but one that could mitigate some issues, is a 
“Patient/Consumer television control device” as suggested by Guessous & Dash (2015). 
This device would allow consumers to make an individualized and informed decision 
about whether or not they want to watch TV with DTC advertisements. The authors state 
that this would not only respect the First Amendment, but it would also respect the 
individual choices made my consumers. Furthermore, they acknowledge that now it is 
common practice for TV and Internet content to be profiled, and that this same practice 
could be applied to health related content as well. However, in regards to the Internet, this 
policy could be tricky as there are currently no regulations regarding online drug 
advertisements because they are a lot harder to control and regulate as the Internet 
surpasses boundaries established by different countries (Khosla, P. & Khosla, A., 2011). 
The issue of DTC advertisements is complicated with patients’ increased use of the 
Internet. Patients understandably want to know more about and become more involved 
with their healthcare, and this medical value is called patient autonomy. Whether or not 
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patient autonomy inhibits or helps with physician-patient relationships will soon be 
discussed.   
The increased role of the patient participation in healthcare was discussed briefly in 
Chapter III. The idea of patient autonomy itself is a relatively new idea in healthcare. It 
was not until 1980 that a revision in the American Medical Association Code of Ethics 
explicitly stated physicians are required to respect patients’ autonomy. Furthermore, 
medical education is placing greater emphasis on physician-patient relationships that 
focus on shared-decision making that respects patient autonomy (Magnezi et al., 2014). 
Patient autonomy itself is defined as “the patient’s right to involvement in the discussion 
and decision-making process during consultation.” In addition, it is the ability for the 
patient to have discussions without being heavily influenced by any healthcare providers 
(Agarwal & Murinson, 2012). There are several reasons as to why patient autonomy has 
become more prevalent in healthcare, including an increased rate of chronic illnesses, the 
patients’ rights movement, and increased Internet usage (Arney & Lewin 2013). Because 
of increased Internet usage, there are some patients, particularly those who are educated, 
who will have an increased medical knowledge. However, this is not the case for 
everyone. Although more people have access to the Internet and can therefore learn more 
about their medical conditions, it does not always mean that patients fully understand 
their medical conditions. Thus, there is some disparity with how much medical 
knowledge patients actually know despite the increase in Internet usage. In addition, the 
Internet does not always present accurate and correct information, and not every patient 
will know how to screen for correct information. Therefore, physicians have to respond 
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appropriately in order to develop and maintain physician-patient relationships that serve 
the best interest of the patient.  
Thus, new models are being created to address the increased amount of information 
patients have, before they visit their physicians. One model proposed by Agarwal & 
Murinson (2012) addresses patient value, patient autonomy, and patient knowledge. The 
authors suggest that by utilizing this model, physicians can better interact with their 
patients. For example, if the patient knowledge is low, then the physician can provide 
more medical knowledge to the patient and in a greater context. In addition, physicians 
can direct patients to more reputable sources.  How does this model come into play when 
the information the patient has is from DTC advertisements? How should doctors respond 
to a patient’s demands for a specific drug they saw advertised?  
One study conducted by Arney & Lewin (2013) looks directly at the portrayal of 
physician-patient relationships in DTC advertisements. The authors were trying to 
identify how doctor-patient relationships were depicted in drug advertisements and then 
also get an opinion of the types of relationships the patients themselves wanted. They 
analyzed DTC advertisements directly and then also conducted interviews with 36 
inviduals. The researchers identified four different physician-patient relationship models 
while interviewing respondents to examine how consumers receive DTC advertisements. 
Those four models are physician-as-confidant, consumer-and- supplier, scientist-and-
specimen, and patient-as-autocrat. The physician-as-confidant model shows a high 
emotional connection between the patient and the physician while the consumer-and-
supplier showed a relationship based off of negotiation. These are the two models that are 
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predominantly found in DTC advertisements. The consumer-and-supplier model was 
found in 30% of DTC advertisements. The respondents viewed the physician-as-
confidant model as an idealized relationship but one that they did not actually have. The 
last two model types are not found in DTC advertisements, but respondents in the 
interviews mentioned them. The scientist-and-specimen model places the physician in 
complete control, and this model was preferred by 39% of respondents. The patient-as-
autocrat model is characterized by patients questioning their doctors and patients often 
seeking health information on their own. This model was identified by 25% of 
respondents. Interestingly, women preferred this model more while men preferred the 
scientist-and-specimen model more. Despite the four different models, respondents 
primarily described the physician-as-confidant model as an ideal rather than what they 
actually have. The authors suggest that the pharmaceutical companies are capitalizing on 
these types of advertisements because it encourages patients to discuss treatment options 
with their doctors. Although this is considered a good thing, it is solely focused on the 
specific treatment advertised, which may not necessarily be in the best interest of the 
patient.  
Although there are different models and different ideas of how physicians can 
respond to patients’ increased medical knowledge and demands for different treatments, 
how physicians put that into practice can vary. Getting insight from a currently practicing 
physician can shed some light on how physicians should respond to their patients and 
what should be done with DTC advertisements as a whole. Therefore, the next section 
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contains the summary of an interview I conducted with Dr. Robin Dickinson, who 
practices medicine in Denver, Colorado.  
Dr. Dickinson practices family medicine. More specifically, she practices what is 
called community supported family medicine or direct primary care (DPC). She provides 
medical services to her patients, who pay a monthly membership fee. DPC differs from 
concierge medicine because each DPC practice fits the needs of the population it is 
serving. Thus, her practice is especially equipped for providing care to patients who do 
not have insurance and cannot otherwise afford healthcare. Dr. Dickinson first wanted to 
be a doctor when she was 6 years old. Growing up in an abusive home, she did not realize 
that being a doctor was a possibility, but it was her mother who told her that she could. 
She attended the University of Denver for her undergraduate education, and she went to 
the University of Colorado for medical school. At first she thought she wanted to be a 
pediatrician because of her experiences growing up, but she soon realized that family 
medicine is what she was the most passionate about. Through family medicine, she could 
address all aspects of a patient’s life and provide the best possible care. She completed 
her residency in Pueblo and soon began working at a family medicine practice. It was 
while working at that practice that she thought about opening her own practice; although, 
at first, she never thought that she would. While at that practice, she soon realized that 
there were some constraints that she felt could hinder the care that she wanted to provide 
to her patients. Thus, she took the necessary steps to open her own practice.  
 Because of her unique perspective on medicine, I believe that she could provide 
some insight into DTC advertisements and how they are affecting doctor-patient 
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relationships. She first discussed how at the old practice, drug representatives would 
come in to talk to the doctors and would always provide free lunch. She said that the 
doctors were essentially trained to view the drug representatives as nice people and to 
like the drug representatives. That is, the physicians and staff who had been there longer 
than she had told her that they want her to like them; no one ever did anything differently. 
However, when she noticed that one of the physician assistants (PA) did not attend these 
lunches, she was curious as to why. This PA said that the representatives were using 
manipulative tactics to get the physicians to use their drugs and that it could look bad to 
the patients if they were receiving these free lunches from drug representatives. This was 
prior to the new law passed under the Affordable Care Act, the Sunshine Act. The 
Sunshine Act requires all pharmaceutical and medical device companies to report any 
payments that doctors receive to the public if the amount is over $10 (Cochran, 2014). 
After the law was passed, the practice actually voted on whether or not it should get rid of 
lunches. It decided that each doctor could individually decide whether or not they wanted 
to attend, and if not enough people were attending, the problem would be readdressed. 
Dr. Dickinson said that as far as she knew, she was the only physician who sat out those 
lunches.  
 The aforementioned narrative is what fueled Dr. Dickinson’s desire to open her 
own practice. Most of the patients she sees now are of a lower socioeconomic status. 
Thus, she found that patients requesting specific prescriptions were not as frequent. In 
fact, Kaphingst & DeJong (2004) reported that for print advertisements, “college-level 
reading ability would be needed to read the average brief summary section.” So even 
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though print advertisements are more accessible than television advertisements for people 
with a lower socioeconomic status, they would still be unable to comprehend the risks 
associated with taking certain drugs because the language used to describe the risks are 
above their reading level. This is why Dr. Dickinson makes it a point to thoroughly 
discuss with every patient why he/she came into see her because she recognizes that her 
patients are not going to be knowledgeable about their medical conditions or about the 
risks associated with certain drugs. Thus, she makes it a point to thoroughly educate her 
patients as much as she can about their conditions and about the drugs that they will use 
to help with their medical conditions. If a specific drug is requested, she goes through the 
entire process of why the patient may or may not need that drug. She emphasizes that her 
appointments are just as much about educating the patient as they are about treating the 
patient.  
 Thus, in regards to DTC advertisements, Dr. Dickinson says that the practice as a 
whole should be put to a stop. Even if changes are to be made, the pharmaceutical 
companies will most likely find ways around them. Instead, she believes that physicians 
should look towards educating their patients about the reasons for their visits and also 
educate patients about the drugs that they may be requesting. She emphasizes that 
treating a patient is about building a relationship and establishing trust with the patient in 
order to fully disclose health information, which will lead to the best treatment. Even if 
that means spending more time with a patient that may seem necessary, it has to be done 
in order to serve the best interests of the patient.  
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 Of course, this is only the opinion of one physician, but Dr. Dickinson brings up 
some valuable points. Although I, myself, am not sure of what type of practice I would 
like to open or even the field of medicine I want to go into, I admire the way that Dr. 
Dickinson treats her patients. I especially like her emphasis on education and really 
working with patients to address their illnesses. Spending more time getting to know and 
educating patients is essential to providing them with the best possible care. Moving 
forward, with an increase in medical technology, the advent of personalized medicine and 
with an increase access to medical knowledge, DTC advertisements may eventually 
become irrelevant.  
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V. Personalized Medicine 
Personalized medicine is the “selection of treatment best suited for an individual, 
involves integration and translation of several new technologies in clinical care of 
patients” (Jain, 2015). The term itself is used interchangeably with several other terms, 
including but not limited to, “precision medicine”, “individualized medicine”, and 
“stratified medicine”. These terms were initially used in specific contexts but have 
merged together to generally identify the same thing (Abettan, 2016). Advances in 
chemistry, biochemistry, and genetics, among others, have allowed for personalized 
medicine to formulate. With the advent of genomics, the human genome project had been 
completely sequenced by 2001. Following the completion of that project began the 
ENCODE project (Encyclopedia of DNA Elements) which aimed to described all of the 
functional elements in the human genome (Jain, 2015). The results of these projects 
provided scientists with important insights into the functions of genetics and DNA, and 
how manipulations in the genetics code can result in various diseases. Being able to 
pinpoint how a disease was caused in one given individual and finding techniques to treat 
this particular disease on a molecular level using various molecular biology techniques 
lead to the birth of personalized medicine.   
Since then, there is more emphasis being placed on researching personalized 
medicine. In 2015, President Obama announced that there would be new funding, $216 
million worth for the fiscal year 2016, for the National Institute of Health, the National 
Cancer Institute, and the FDA. The Precision Medicine Initiative has short-term and long-
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term goals. The short-term goals include more research on personalized or precision 
medicine for cancers while the long-term goals are focused on bringing personalized 
medicine to a large scale for healthcare (U.S. National Library of Medicine, 2015).  
Much like the field of medicine has evolved over times, doctor-patient 
relationships have also changed. While direct-to-consumer drug advertisements currently 
serve to complicate doctor-patient relationships, personalized medicine has the potential 
to further complicate this precious relationship. Of course, there is also the potential for 
personalized medicine to strengthen doctor-patient relationships. More specific 
information about patients will be known by physicians, and it is what physicians do with 
that information that can either strengthen or weaken their relationships with patients. 
There is the potential for physicians to only address their patients by the information they 
receive. That is, patients will only be seen as their genetic information rather than as a 
whole person. With the specificity that personalized medicine offers, physicians have to 
be aware that regardless of the specific problem they are addressing, it still impacts the 
patient as a whole. Therefore, physicians still have a responsibility to treat and care for 
their patients as a whole despite the specificity that personalized medicine offers.   
With that in mind, DTC advertisements will add another layer of complexity to 
doctor-patient relationships but in the context of personalized medicine. DTC 
advertisements can continue to be misleading about what personalized medicine has to 
offer. Although personalized medicine has the potential to radically change medicine, its 
full potential must not be overstated. There are still limits to personalized medicine, and 
patients have to be aware of that. However, as medicine continues to move towards 
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personalized medicine, pharmaceutical companies could further utilize DTC 
advertisements to capitalize on the advantages of personalized medicine for their own 
personal gain.  
 Direct-to-consumer advertisements have evolved with the field of medicine. 
Although the field of medicine itself has been around significantly longer than DTC 
advertisements, the two now coexist. The field of medicine will most likely continue to 
evolve, and it will be interesting to see whether or not DTC advertisements evolve with 
it. The direction that medicine seems to be heading is toward personalized medicine. If 
DTC advertisements are altered, or perhaps removed altogether, as a result of 
personalized medicine, what implications does that have on doctor-patient relationships? 
Does personalized medicine itself add to doctor-patient relationships?  
It seems that because of the significant funding allocated for personalized 
medicine there would be benefits for the practice and many believe that personalized 
medicine has the potential to revolutionize healthcare. However, there are new concerns 
with whether or not funding will remain in place because of the new Trump 
administration. One article states that there is bipartisan support for personalized 
medicine, but this still does not completely ease concerns, as the administration could 
potentially not agree with either party. A 2017 appropriations bill regarding funding for 
the Precision Medicine Initiative was not passed, but rather, continuing resolutions that 
were established prior for funding were put in place until March 31, 2017 (Ray, 2016). 
This is not completely unusual during an election year, but some are worried that major 
changes will happen to the 2017 budget, which could have a significant impact on 
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ongoing research. In addition, some worry that funding will be cut entirely because some 
Republicans might see it as another effort to heighten Obama’s legacy (Ray, 2016). Thus, 
it remains to be seen if current research, as funded by the federal government, will 
continue.           
 Personalized medicine can potentially be beneficial to many people. Abettan 
(2016) discusses how it could potentially be a paradigm shift in medicine. Advances in 
genetic knowledge can allow for more accurate prescriptions for patients. That is, 
prescriptions can be produced that specifically fit an individual’s genotype, and in turn, 
adverse side effects can be greatly reduced. This would require active participation by 
pharmaceutical companies because they are the ones producing more effective medicines 
with fewer side effects (USFDA, 2013). However, if pharmaceutical companies are not 
willing to invest in personalized treatments, then the process could be hindered. 
Pharmaceutical companies would have to find new drug therapies that replace existing 
and profitable ones, which may not appeal to some companies (Jameson & Longo, 2015). 
Fortunately, it seems that more companies are wiling to invest in more personalized 
medications. For example, a drug used by HIV patients, Abacavir, is safe for all but 6 
percent of patients who develop serious allergic reactions. Researchers found that a single 
genetic variant was causing the reaction and now HIV patients are screened for that 
genetic variant before they are prescribed Abacavir (Abettan, 2016). Personalized 
medicines also attempt to give patients the right drugs at the right time (USFDA, 2013). 
To go a step even further, supporters of personalized medicine believe that it can go from 
reactive to preventative medicine. By utilizing genetic testing, doctors can earlier predict 
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the risk for some patients of developing a specific disease (Abettan, 2016). As more of 
these genetic tests become available, it is likely that pharmaceutical companies will begin 
to put their own genetic tests on the market. However, the testing as well as the therapies 
that are done needs to be safe and effective, and the FDA is implementing new research 
regulations and standards in order to ensure this (USFDA, 2013).   
As with any change in medicine, there are going to be some who do not see the 
benefits or have serious questions about personalized medicine and what it means for the 
field as a whole.  One concern with personalized medicine is the cost. One study claims 
that healthcare costs would be reduced with personalized medicine if the focus is on 
prevention over therapy, but other studies have shown that genetic information can lead 
to an increase in physician visits which results in more laboratory tests and increases 
patient anxiety (Joyner & Paneth, 2015). Those increase in physician visits and laboratory 
tests could potentially lead to the patient paying more to cover those costs. In addition, 
there is also concern with the cost of the therapies themselves. Currently, new, targeted 
cancer drugs can cost up to $100,000 a year (Joyner & Paneth, 2015). However, it can 
reduce the likelihood of treatment failure thus resulting in less money spent over the long 
term. Also, there is a likelihood for safer clinical trials which reduces the risk of serious 
side effects which again, can reduce healthcare costs in the long run (Shoaib et al., 2016). 
It is understandable that there are concerns with the costs associated with personalized 
medicine, and it is a concern that would have to be monitored moving forward.       
 Not only are there concerns with what costs might be associated with personalized 
medicine, there are also some ethical concerns. One of them relates access to genetic 
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information. There is the possibility that individual’s genetic information would be 
available to a wide number of people (Jain, 2015). It is also possible that patients would 
only be seen as genetic information as opposed to whole people who have differing 
opinions and emotions. This is worrisome for some physicians who argue that it could 
lead to a technical communication with patients as opposed to individualized 
communication (Abettan, 2016). There is also concern with the information patients 
actually receive from any genetics tests they have done. There is a potential for there to 
be incidental findings. In one survey, a majority of patients wanted to be asked what 
information they would like to receive. That is, some patients do not want to know about 
some information that is found in the genetic tests, and physicians have a responsibility to 
respect their patients’ wishes (Shoaib et al., 2016). 
 In addition to the aforementioned concerns, there are also some ethical concerns 
with the information found during genetic tests and what it could mean for healthcare as a 
whole. There is concern with who would have access to patients’ genetic information and 
how it would be used. To address these concerns, the U.S. Congress passed the Genetic 
Information Nondiscrimination ACT (GINA) in 2008. This legislation prevents insurance 
companies from using a person’s genetic information in determining eligibility or 
premiums, requiring or requesting a genetic test, or employers using genetic information 
to make employment decisions. However, there are worries that the bill would be 
difficult to enforce, and it does not discuss long-term care insurers or life insurers. The 
Affordable Care Act would prevent insurance companies from using preexisiting 
conditions, whether they are genetic or not, to establish premiums (Jain, 2015). If 
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companies were found to be in violation of the act, they will have to pay a fee as a well as 
take measures to fix the mistake (Shoaib et al., 2016). Prior to the Affordable Care Act, 
insurance companies could deny individuals with preexisting conditions. Moving 
forward, this is something these are factors that will need to be considered when the laws 
governing healthcare have the potential to change at any time.         
 There are significant implications personalized medicine can have on healthcare, 
but more people need to actually know about the practice before some of those 
implications can be understood. Now, a multitude of top institutions are creating 
campaigns to market advances in personalized medicine (Wolinsky, 2015). These 
advertisements can potentially be very harmful to patients because patients can misuse 
the test, misinterpret the results, and not follow-up on the results with a physician. 
Furthermore, there is concern that the DTC genetic screening tests may not be as accurate 
as laboratory tests (Jain, 2015). That is, laboratory tests are done by trained professionals 
with access to much more precise as sophisticated tools as opposed to the DTC genetic 
screening tests performed at home. Much like DTC advertisements, there needs to be 
regulation by the FDA for DTC genetic testing. One review of marketing genomic 
campaigns found that many advertisements were very close to being deceptive and 
potentially unethical (Wolinsky, 2015). In Europe, a survey was conducted which showed 
that a majority of clinical geneticists do not believe that DTC genetics tests are clinically 
useful and that certain test should be more carefully regulated or banned altogether. They 
believe that DTC genetics tests should be required to undergo the same procedure that 
DTC pharmaceuticals do for market introduction (Jain, 2015). Ultimately, it is clear that 
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careful consideration needs to be put into advertisements for DTC genetic screening tests. 
Even institutions themselves have to be considerate of the claims they are making in 
regards to personalized medicine and provide full disclosure as to whether or not their 
therapies will benefit a particular patient.       
 With that in mind, it is evident that personalized medicine will have some impact 
on doctor-patient relationships. As was mentioned earlier, patients are taking a more 
proactive role in managing their healthcare because of their increased access to the 
Internet for information. Of course, this does not always mean patients fully understand 
the information that they are being presented, but there is the potential for patients to 
become more knowledgeable about their healthcare. If patients do have an increased 
medical knowledge, they may want treatments and/or therapies that are specifically 
designed for them or that may not be as harmful. On the other hand, some patients may 
not be as actively involved in their healthcare. Regardless, it is essential for physicians to 
remember that an important part of personalized medicine is caring for the whole person, 
including the patients’ views and lifestyles in addition to their health (Pokorska-Bocci et 
al., 2014). Pokorska-Bocci et al. (2014) maintain that clinical medicine will continue to 
be a process of choosing the best care for the patient and that biomedical sciences will 
help refine the process. The best care given still has to be what is the best suited for the 
patient’s health, preferences, and circumstances; that is determined by fostering a 
dialogue between the patient and the physician. Thus, personalized medicine can only be 
achieved when all aspects of the patient are taken into consideration (Abettan, 2016). If it 
is, personalized medicine has the potential to strengthen physician-patient relationships. 
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Patients would only be given medications that are guaranteed to better the patient, and 
patients would be more willing to listen to their physician and follow the treatment 
regimen (Shoaib et al., 2016). However, this is still dependent on a dialogue between the 
physician and the patient. Ultimately, even though personalized medicine may become 
the future of medicine, it is still dependent on an established relationship between the 
physician and the patient that determines the best suitable treatment for that patient. Even 
as personalized medicine continues to advance, physicians should still view their patients 
as patients as opposed to test subjects whose only purpose is to advance the field.    
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Final Thoughts  
 The field of medicine has a long history, and beginning with the Hippocratic 
Oath, it has developed and progressed to the practice that we recognize today. It has 
evolved from a practice based on primarily superstitious and religious beliefs to one 
guided by science and scientific research. The advent of technology has further evolved 
the field of medicine. With the completion of the human genome project, medicine has 
the potential to revolutionize how we treat patients. The field of medicine is unlike any 
other, and those who choose to enter the field have a tremendous responsibility. 
Unfortunately, there are many other factors that have influenced the field that have 
caused some physicians to stray away from what it really means to be a physician. Of 
course, this is not the case for every physician, but it has become widespread enough that 
it is something that needs to be addressed. One of those factors is DTC advertisements.  
Beginning my research on DTC advertisements, I was not really sure what I 
would find. I was not even sure that I was particularly against them or what they really 
had to do with doctor-patient relationships. However, it soon became clear that they do, 
in fact, have a significant impact on the healthcare field and can be potentially disruptive 
to doctor-patient relationships. While I maintain that DTC advertisements should be 
eliminated altogether because of the overall negative impacts they can have, it does not 
seem like a realistic action that will happen any time soon. Therefore, I think that it 
becomes the duty of the physicians to ultimately negate them and decide what is best for 
their patients. It is necessary for physicians to develop relationships with their patients 
 65 
and develop an understanding that patients are so much more than their medical 
condition. This becomes increasingly important with patients’ increased access to 
healthcare information because of easier access to information found on the Internet. 
Physicians will have to learn to navigate and work with their patients to determine which 
information is actually beneficially to them.  
 It may seem that I am being especially critical of physicians, but in today’s world, 
where pharmaceutical companies’ sole purpose is to make a profit, physicians are 
challenged to rise above that notion and care for their patients regardless of any financial 
profit. Physicians have been given a special role in society to care for people, and they 
should be taking that role seriously. Physicians should be working closely with patients, 
educating them about their illnesses. Establishing relationships with patients makes it 
more feasible to physicians to successfully treat them  
After completing all of my research, I feel confident working towards my goal 
that I have a better understanding of the medical field and the role of the physician as a 
whole. Although it might not be easy, I believe that being the successful physician is 
possible. Establishing relationships with patients and educating them is the best way to 
help treat them. Included in that is treating patients with the understanding, compassion, 
and respect that they deserve. The medical field and even the pharmaceutical industry 
will continue to change and evolve, but the most important thing to remember is, 
ultimately, what the role of the physician should be
 66 
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